In the September 25, 2017, issue of The ASCO Post, page 1, the date of approval was cited incorrectly for the genetically engineered T-cell therapy tisagenlecleucel (Kymriah). The U.S. Food and Drug Administration approved tisagenlecleucel on August 30, 2017. The T-cell therapeutic is approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. The ASCO Post regrets this typographic error. ■